HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Executive Summary

Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.

You may also be interested in...



US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects

FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.

Without US CBD Guidance, Low-Quality Supplements, State Rules Hurt Industry

Responsible CBD supplement marketers are disadvantaged against bad actors with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.

Congress Ready To Propose Legislation To Deliver US FDA’s Wish: Allowing CBD Use In Supplements

House Energy and Commerce members are expected soon to introduce a bill to make lawful the use of CBD and other hemp-derived ingredients, other than THC, in dietary supplements. Capitol Hill interest in proposing legislation, says Sen. Wyden , will grow if FDA doesn’t bring some order to the CBD space.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel